TR200003779T2 - Transkripsiyon faktörü NF-kB inhibitörleri - Google Patents

Transkripsiyon faktörü NF-kB inhibitörleri

Info

Publication number
TR200003779T2
TR200003779T2 TR2000/03779T TR200003779T TR200003779T2 TR 200003779 T2 TR200003779 T2 TR 200003779T2 TR 2000/03779 T TR2000/03779 T TR 2000/03779T TR 200003779 T TR200003779 T TR 200003779T TR 200003779 T2 TR200003779 T2 TR 200003779T2
Authority
TR
Turkey
Prior art keywords
inhibitors
disease
diseases
amino
transcription factor
Prior art date
Application number
TR2000/03779T
Other languages
English (en)
Inventor
Francis Callahan James
C.Chabot-Fletcher Marie
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200003779T2 publication Critical patent/TR200003779T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Bu bulus, trankripsiyon faktörü NF-kB nin farmasötik olarak kabul edilebilir tuzlari, hidratlari ve solventlerinin amino-indanon inhibitörlerini, bu bilesimlerin terkiplerini ve NF-kB aktivasyonunun rol oyandigi hastaliklari tedavi yöntemleri saglamaktadir. Bu bulus özellikle örnegin enflamatuar hastaliklarin, özellikle romatizmal artrit, enflamatuar barsak hastaligi, ve astim; sedef hastaligi ve atopik dermatil dahil, dermatoz; oto-immün hastaliklar; doku ve organ reddi; alzheimer hastaligi; felç; ateroskleroz; restenoz; kanser ve Hodojken hastaligi; bazi viral enfeksiyonlar, AIDS dahil; osteoartrit; osteoporoz; ve Ataxia Telangiestasia gibi NF-kB aktivasyonuyla baglantili çesitli hastaliklarin, ihtiyaci olan hastaya bir bulus bilesimi verilmesi için yöntemler saglar.
TR2000/03779T 1998-06-19 1999-06-18 Transkripsiyon faktörü NF-kB inhibitörleri TR200003779T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
TR200003779T2 true TR200003779T2 (tr) 2001-06-21

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03779T TR200003779T2 (tr) 1998-06-19 1999-06-18 Transkripsiyon faktörü NF-kB inhibitörleri

Country Status (17)

Country Link
EP (1) EP1085872A4 (tr)
JP (1) JP2002518333A (tr)
KR (1) KR20010052990A (tr)
CN (1) CN1306428A (tr)
AR (1) AR019871A1 (tr)
AU (1) AU4699699A (tr)
BR (1) BR9911151A (tr)
CA (1) CA2335293A1 (tr)
CO (1) CO5080752A1 (tr)
CZ (1) CZ20004760A3 (tr)
HU (1) HUP0102492A2 (tr)
IL (1) IL140324A0 (tr)
NO (1) NO20006452L (tr)
PL (1) PL345577A1 (tr)
TR (1) TR200003779T2 (tr)
WO (1) WO1999065495A1 (tr)
ZA (1) ZA200007448B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP1076699B1 (en) 1998-05-14 2008-10-29 Immunex Corporation Method of inhibiting osteoclast activity
ATE369844T1 (de) * 2000-01-24 2007-09-15 Genzyme Corp Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1989203A2 (en) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
WO2010108058A2 (en) * 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
CA2769038A1 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2012109527A2 (en) 2011-02-10 2012-08-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
EP1085872A4 (en) 2003-04-16
HUP0102492A2 (hu) 2001-11-28
BR9911151A (pt) 2001-03-06
NO20006452L (no) 2001-02-16
IL140324A0 (en) 2002-02-10
EP1085872A1 (en) 2001-03-28
KR20010052990A (ko) 2001-06-25
WO1999065495A1 (en) 1999-12-23
AU4699699A (en) 2000-01-05
CO5080752A1 (es) 2001-09-25
PL345577A1 (en) 2001-12-17
JP2002518333A (ja) 2002-06-25
CZ20004760A3 (cs) 2001-08-15
ZA200007448B (en) 2001-12-12
CA2335293A1 (en) 1999-12-23
CN1306428A (zh) 2001-08-01
NO20006452D0 (no) 2000-12-18
AR019871A1 (es) 2002-03-20

Similar Documents

Publication Publication Date Title
TR200003781T2 (tr) Transkripsiyon faktörü NF- kB inhibitörleri
PT1115701E (pt) Ureias de arilsulfonanilida
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
WO2001042231A3 (en) Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
NO995543L (no) Monoestere fra probukol for behandling av kardiovaskulær og inflammatorisk sykdom
TR200102967T2 (tr) Substitüsyonlu azollar
MY138352A (en) Benzothiazole derivatives
IL183340A0 (en) [1,2,4] triazolo[4,3-a] pyridine derivatives and pharmaceutical compositions containing them
IS6852A (is) Efnasambönd
BR0111544A (pt) Heterociclos bicìclicos 6,5-fundidos
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
BRPI0415185A (pt) 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
PT1005453E (pt) Compostos de benzeno substituido como agentes de reducao antiproliferativa
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
TR200102131T2 (tr) Matrisk metaloproteinaz inhitörleri olarak 2,3,4,5-tetrahidro-1H[1,4] benzodiyazepin-3- hidroksamik asitler.
BR9908882A (pt) Bisindolimaleimidas substituìdas para a inibição de proliferação de célula
BR9911151A (pt) Inibidores do fator de transcrição nf-kb
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
NZ330944A (en) Peptide derivatives
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
BR0316196A (pt) Diidrofenantridinasulfonamidas substituìdas
ATE248845T1 (de) Arylsulfonanilid-phosphate
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina